Complementary
mechanisms
Dynamic Restoration
of the Chronic Wound
Microenvironment
From chronicity toward regeneration.
HEALING EVOLUTIONDAY 0
THE LEAD PRODUCT · TOPICAL THERAPY
First-in-Class
Explore the product experience →
First-in-Class
Topical
Hydrogel
A multi-mechanism formulation designed to restore the chronic wound microenvironment through direct, clinician-guided application.
01
RestoreMoves the wound from chronicity toward regeneration.
02
ProtectAddresses infection, inflammation and pain together.
03
RegenerateSupports granulation and re-epithelialization.
THE MULTI-MECHANISM APPROACH
All-in-onesolution
Chronic wounds are sustained by multiple interconnected factors. UNTECH is designed to address them simultaneously—not one at a time.
THERAPEUTIC SYSTEM
12
4
1
Coordinated
dimensions
Integrated
response
01Infection control
Wide-spectrum biofilm inhibition and disruption
Wide-spectrum bacteriostatic and bactericidal action
Protease activity regulation
02Microenvironment restoration
↑ In situ oxygenation
Wound-bed acidification toward a healing pH
Free-radical scavenging
03Tissue regeneration
Displacement from the chronic inflammatory state
↑ Granulation tissue formation
↑ Re-epithelialization
04Patient & wound management
↓ Neuropathic and nociceptive pain
Exudate management
Activation of autolytic debridement
Global access strategy
International
International
Footprint
Building the right partnerships to take a new wound-care platform from scientific innovation to patients around the world.
FROM LAB TO PATIENT
RESEARCH & DEVELOPMENT
Science-driven
01
02
03
Science-driven
Patient-centered
Our therapy is the result of years of research and development—guided by one principle: create the best possible treatment for patients.
Scientific rigor
Every stage is carefully refined around the biological complexity of chronic wounds.
Real-world relevance
Development decisions reflect the challenges clinicians and patients face every day.
Quality at scale
Designed for consistent development under rigorous GMP standards.
Excellence in science only matters when it delivers real outcomes for patients.
CLOSED STRATEGIC PARTNERSHIP · LATIN AMERICA
Untech + Elea.Latin America, secured.
A closed partnership with one of Latin America’s leading pharmaceutical companies.
From development and regulatory execution to manufacturing, commercialization and patient access.
STATUSClosed strategic partnership
REGIONLatin America
PATHWAYDevelopment to patient access
UNTECH+Elea
Closed Strategic PartnershipLATIN AMERICA
GLOBAL HEALTH CHALLENGE
Global unmet
167Mpeople with diabetes are estimated to develop diabetic foot ulcers
1 in 3may become hard-to-heal chronic wounds
1 in 5hard-to-heal diabetic wound cases may result in amputation
Global unmet
medical need.
Every 20 secondssomeone loses a limb due to a chronic wound.
For millions of people, today’s standard of care still manages the wound without resolving the disease that keeps it chronic.
The burden extends across diabetic foot ulcers, venous leg ulcers and pressure ulcers—bringing chronic pain, disability and the risk of amputation.
€80–90Bannual spend treating chronic wounds
across Europe and the US
across Europe and the US
THE COST OF THE STATUS QUO
Current treatments remain costly
and don’t ensure healing.
A large inefficient marketready for disruption.
THE PROBLEM / 01CHRONIC WOUND CARE
Chronic &
hard-to-heal
wounds.
A global problem that crosses geographies and socioeconomic groups.
The burden is growing, driven by diabetes, obesity and population ageing. For millions of patients, a wound becomes more than a local injury: it can remain open when the body's normal repair process is disrupted.
120M+
INDICATIVE GLOBAL SCALE
People potentially affected by chronic and hard-to-heal wounds, depending on how prevalence is defined and estimated.
THREE MAJOR PRESENTATIONS
Different origins.
A shared failure to heal.
01 / DIABETESDiabetic foot
Diabetic foot
ulcers.
Neuropathy, reduced blood flow and repeated pressure can turn a small injury into a persistent foot wound.
02 / CIRCULATIONVenous leg
Venous leg
ulcers.
Impaired venous return can sustain swelling and inflammation in the lower leg, slowing tissue repair.
03 / IMMOBILITYPressure
Pressure
ulcers.
Prolonged pressure and shear can reduce tissue perfusion, especially over bony areas such as the heel.
WHY WOUNDS BECOME CHRONICHealing is a system.
Healing is a system.
So is the problem.
Underlying conditions disrupt the body's natural healing process. Diabetes, poor circulation and prolonged pressure create interconnected barriers that can trap wounds in a cycle of chronicity.
WHEN BARRIERS PERSIST
Without addressing these factors together, wounds may enlarge, become infected and, in severe cases, lead to amputation.
Medical illustrations are generated, not patient photographs or diagnostic references. The 120M+ figure is an indicative extrapolation from published estimates of 1–2% global prevalence; methods and definitions vary. Prevalence context · Clinical burden context.
THE SHIFT IN CHRONIC WOUND CAREMillions of patients don’t need better dressings— they need a new therapeutic paradigm.
FROM PALLIATION→TO HEALING
One Product
Multi Mechanism
Real Healing
PRODUCT EXPERIENCE · CONCEPT
UNTECH
UNTECH
Topical Hydrogel
A new way to approach chronic wound care, designed for direct topical application within a healthcare professional’s treatment plan.
PRESENTATION30 g tube
FORMATTopical hydrogel
INSIDE THE BOX
01
30 g tubeTransparent topical hydrogel in a controlled-dispensing tube.
02
Product informationClinician-directed preparation, application and wound-care guidance.
Living with a chronic wound? A clinician should assess the wound before any treatment is used. This purchase journey is a preview of the future patient experience.
Concept preview · Not currently available for sale
UNTECH JOURNALNews
News
& updates
Milestones in science, partnerships and the path toward a new standard of chronic wound care.
ABOUT UNTECH · OUR VISION
Built to move
01Whole-system
thinking
02Patient-defined
innovation
03Healing
at scale
Built to move
healing forward.
Untech is a drug development company rethinking chronic wound care from the biology up.
We address the wound as an interconnected microenvironment—not a collection of isolated symptoms—to help patients move beyond chronicity toward true healing.
thinking
innovation
at scale
ONE TEAMScience. Execution. Patient impact.
OUR STORY
Born from science.
Built to change healing.
Untech began with a question that medicine had left unanswered for too long: why do some wounds remain trapped in chronicity? From a university laboratory in Argentina, our founders set out to understand the wound as a complete biological system — and to create a therapy capable of changing its course.
A scientific insight
Research at CONICET and the National University of Tucumán reveals that chronic wounds must be treated as a complex, self-sustaining microenvironment.
Science becomes Untech
Rubén Salim Brovia and Dr. Alberto Ramos Vernieri bring business and science together to transform that discovery into a scalable biotechnology company.
One product, multiple mechanisms
Years of development lead to a first-in-class topical hydrogel designed to act simultaneously on the factors that keep a wound from healing.
From Argentina to global impact
International patents, strategic partners and clinical development move Untech closer to its purpose: restoring healing and making it accessible worldwide.
We did not set out to make another dressing.
We set out to change the biology of chronic wounds.
Global Awards
& Recognition.
Untech has been distinguished by leading institutions across science, innovation and entrepreneurship.
Partner with us
We are expanding our international presence beyond Latin America and actively seeking partners across the United States, Europe, and Asia to bring this therapy to patients worldwide.
If you are a clinician, investor, or industry partner interested in advancing the future of wound care, we would welcome the opportunity to connect.
Email: info@untech.bioAddress: Suipacha 1111, CABA, Argentina
LinkedIn: untech-bio